Siirry offline-tilaan Player FM avulla!
Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch
Manage episode 415256981 series 2739469
We love to hear from our listeners. Send us a message.
As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech, the therapeutic proposition of circular, or "O" RNA and why it holds great potential to best linear RNA constructs, the novel, platform- and partnership-based approaches Orna is taking to address B-cell lymphomas and Duchenne Muscular Dystrophy, viral vector and lipid nanoparticle complexity, and a whole lot more.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
Luvut
1. Circular RNA Biotech Innovations (00:00:00)
2. Innovations in RNA-based Gene Editing (00:07:59)
3. Advantages of Circular RNA in Biotech (00:13:59)
4. Innovating With Novel Technology Risks (00:22:22)
5. Emerging RNA Cell Therapy Potential (00:28:57)
6. RNA Platform Strategies and Partnerships (00:42:20)
7. Exploring the Future of RNA Therapies (00:48:49)
219 jaksoa
Manage episode 415256981 series 2739469
We love to hear from our listeners. Send us a message.
As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech, the therapeutic proposition of circular, or "O" RNA and why it holds great potential to best linear RNA constructs, the novel, platform- and partnership-based approaches Orna is taking to address B-cell lymphomas and Duchenne Muscular Dystrophy, viral vector and lipid nanoparticle complexity, and a whole lot more.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
Luvut
1. Circular RNA Biotech Innovations (00:00:00)
2. Innovations in RNA-based Gene Editing (00:07:59)
3. Advantages of Circular RNA in Biotech (00:13:59)
4. Innovating With Novel Technology Risks (00:22:22)
5. Emerging RNA Cell Therapy Potential (00:28:57)
6. RNA Platform Strategies and Partnerships (00:42:20)
7. Exploring the Future of RNA Therapies (00:48:49)
219 jaksoa
Kaikki jaksot
×Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.